Session » (1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1032

“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)

9:00AM-11:00AM: Abstract Number: 1020

An Increase in Safety Outcome Trials and the Issue of Informed Consent

9:00AM-11:00AM: Abstract Number: 1019

Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions

9:00AM-11:00AM: Abstract Number: 1028

Barriers to Total Joint Arthroplasty for Patients Residing in High-Poverty Communities

9:00AM-11:00AM: Abstract Number: 1023

Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes

9:00AM-11:00AM: Abstract Number: 1016

Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1017

Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes

9:00AM-11:00AM: Abstract Number: 1025

Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients

9:00AM-11:00AM: Abstract Number: 1031

Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System

9:00AM-11:00AM: Abstract Number: 1015

Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives

9:00AM-11:00AM: Abstract Number: 1013

Implementation of a Rheumatology-Based Social Determinants of Health Screening Program to Uncover and Address Needs in a Multihospital Health Care System

9:00AM-11:00AM: Abstract Number: 1022

Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)

9:00AM-11:00AM: Abstract Number: 1026

Patients’ Barriers to Total Joint Arthroplasty: Associations with the Orthopedic Consultation

9:00AM-11:00AM: Abstract Number: 1030

Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors

9:00AM-11:00AM: Abstract Number: 1021

Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1018

Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 1024

Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry

9:00AM-11:00AM: Abstract Number: 1014

Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities

9:00AM-11:00AM: Abstract Number: 1027

Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis

9:00AM-11:00AM: Abstract Number: 1029

Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].